In vivo-validated essential genes identified in Acinetobacter baumannii by using human ascites overlap poorly with essential genes detected on laboratory media

mBio

Volumn 3, Issue 4, 2012, Pages

  Umland, Timothy C ^a,b   Wayne Schultz, L ^a,b   MacDonald, Ulrike ^b,c   Beanan, Janet M ^b,c   Olson, Ruth ^b,c   Russo, Thomas A ^b,c,d  

^a HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEE GENE; ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER BAYLYI; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AROA GENE; AROC GENE; ARTICLE; ASCITES; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; BACTERIUM ISOLATION; BACTERIUM MUTANT; CARA GENE; CONTROLLED STUDY; CULTURE MEDIUM; DNA SEQUENCE; DNA SYNTHESIS; DRUG TARGETING; ENVZ GENE; EPSA GENE; ESSENTIAL GENE; EX VIVO STUDY; GENE DISRUPTION; GENE FUNCTION; GENE MUTATION; GENE PRODUCT; GENE TARGETING; GENETIC IDENTIFICATION; HUMAN; IN VIVO STUDY; INTRACELLULAR SIGNALING; LABORATORY TEST; NONHUMAN; NUCLEOTIDE SEQUENCE; OMPF GENE; OSTA GENE; PBGG GENE; PRIORITY JOURNAL; PROTEIN TRANSPORT; PTK GENE; PYRC GENE; RAT; RELA GENE; RNA SYNTHESIS; RPMA GENE; RSTA GENE; SECE GENE; SKIN ABSCESS; SPSC GENE; TRMD GENE; UPPP GENE; VALIDATION PROCESS;

ACINETOBACTER BAUMANNII; ACINETOBACTER BAYLYI; ENTEROBACTER SP.; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA; RATTUS;

EID: 84865768680     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00113-12     Document Type: Article

References (67)

1. D'Elia MA, Pereira MP, Brown ED. 2009. Are essential genes really essential? Trends Microbiol. 17:433-438.
2. Dowell RD, et al. 2010. Genotype to phenotype: a complex problem. Science 328:469.
3. Grenov AI, Gerdes SY. 2008. Modeling competitive outgrowth of mutant populations: why do essentiality screens yield divergent results? Methods Mol. Biol. 416:361-367.
4. Osterman AL, Gerdes SY. 2008. Comparative approach to analysis of gene essentiality. Methods Mol. Biol. 416:459-466.
5. Baba T, et al. 2006. Construction of Escherichia coli K-12 in-frame, singlegene knockout mutants: the Keio collection. Mol. Syst. Biol. 2:2006.0008.
6. Gerdes SY, et al. 2003. Experimental determination and system level analysis of essential genes in Escherichia coli MG1655. J. Bacteriol. 185: 5673-5684.
7. Rudd KE. 2000. EcoGene: a genome sequence database for Escherichia coli K-12. Nucleic Acids Res. 28:60-64.
8. Salama NR, Shepherd B, Falkow S. 2004. Global transposon mutagenesis and essential gene analysis of Helicobacter pylori. J. Bacteriol. 186: 7926-7935.
9. Dammel CS, Noller HF. 1995. Suppression of a cold-sensitive mutation in 16S rRNA by overexpression of a novel ribosome-binding factor, RbfA. Genes Dev. 9:626-637.
10. Joyce AR, et al. 2006. Experimental and computational assessment of conditionally essential genes in Escherichia coli. J. Bacteriol. 188: 8259-8271.
11. Zalacain M, et al. 2003. A global approach to identify novel broadspectrum antibacterial targets among proteins of unknown function. J. Mol. Microbiol. Biotechnol. 6:109-126.
12. Hillenmeyer ME, et al. 2008. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320:362-365.
13. Nichols RJ, et al. 2011. Phenotypic landscape of a bacterial cell. Cell 144:143-156.
14. Zhang R, Lin Y. 2009. DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res. 37:D455-D458.
15. Cameron DE, Urbach JM, Mekalanos JJ. 2008. A defined transposon mutant library and its use in identifying motility genes in Vibrio cholerae. Proc. Natl. Acad. Sci. U. S. A. 105:8736-8741.
16. Gallagher LA, et al. 2007. A comprehensive transposon mutant library of Francisella novicida, a bioweapon surrogate. Proc. Natl. Acad. Sci. U. S. A. 104:1009-1014.
17. Langridge GC, et al. 2009. Simultaneous assay of every Salmonella typhi gene using one million transposon mutants. Genome Res. 19:2308-2316.
18. Crowther GJ, et al. 2010. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl. Trop. Dis. 4:e804.
19. Payne DJ, Gwynn MN, Holmes DJ, Rosenberg M. 2004. Genomic approaches to antibacterial discovery. Methods Mol. Biol. 266:231-259.
20. Shen Y, et al. 2010. Blueprint for antimicrobial hit discovery targeting metabolic networks. Proc. Natl. Acad. Sci. U. S. A. 107:1082-1087.
21. Boucher HW, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
22. Garnacho-Montero J, Amaya-Villar R. 2010. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr. Opin. Infect. Dis. 23:332-339.
23. Manchanda V, Sanchaita S, Singh N. 2010. Multidrug resistant Acinetobacter. J. Global Infect. Dis. 2:291-304.
24. Kim BN, et al. 2009. Management of meningitis due to antibioticresistant Acinetobacter species. Lancet Infect. Dis. 9:245-255.
25. Snitkin ES, et al. 2011. Genome-wide recombination drives diversification of epidemic strains of Acinetobacter baumannii. Proc. Natl. Acad. Sci. U. S. A. 108:13758-13763.
26. Towner KJ. 2009. Acinetobacter: an old friend, but a new enemy. J. Hosp. Infect. 73:355-363.
27. Sengstock DM, et al. 2010. Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin. Infect. Dis. 50:1611-1616.
28. Perez F, et al. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:3471-3484.
29. Fishbain J, Peleg AY. 2010. Treatment of Acinetobacter infections. Clin. Infect. Dis. 51:79-84.
30. Boucher H, et al. 2011. 10 X'20 progress: development of new drugs active against resistant 687 Gram-negative bacilli, abstr LB-27. Abstr. 49th Ann. Meet. Infect. Disease Soc. Am. IDSA, Boston, MA.
31. Butler MS, Cooper MA. 2011. Antibiotics in the clinical pipeline in 2011. J. Antibiot. 64:413-425.
32. Russo TA, Carlino UB, Mong A, Jodush ST. 1999. Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine. Infect. Immun. 67:5306-5314.
33. Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ. 2010. Challenges of antibacterial discovery revisited. Ann. N. Y. Acad. Sci. 1213:5-19.
34. Russo TA, et al. 2010. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect. Immun. 78:3993-4000.
35. Russo TA, et al. 2009. Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo. J. Infect. Dis. 199:513-521.
36. Russo TA, et al. 2008. Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology. Infect. Immun. 76: 3577-3586.
37. Altenhoff AM, Dessimoz C. 2009. Phylogenetic and functional assessment of orthologs inference projects and methods. PLoS Comput. Biol. 5:e1000262.
38. Fitch WM. 1970. Distinguishing homologous from analogous proteins. Syst. Zool. 19:99-113.
39. Koonin EV. 2005. Orthologs, paralogs, and evolutionary genomics. Annu. Rev. Genet. 39:309-338.
40. Agüero F, et al. 2008. Genomic-scale prioritization of drug targets: the TDR targets database. Nat. Rev. Drug Discov. 7:900-907.
41. Doyle MA, Gasser RB, Woodcroft BJ, Hall RS, Ralph SA. 2010. Drug target prediction and prioritization: using orthology to predict essentiality in parasite genomes. BMC Genomics 11:222.
42. de Berardinis V, et al. 2008. A complete collection of single-gene deletion mutants of Acinetobacter baylyi ADP1. Mol. Syst. Biol. 4:174.
43. Sebkova A, Karasova D, Crhanova M, Budinska E, Rychlik I. 2008. aro mutations in Salmonella enterica cause defects in cell wall and outer membrane integrity. J. Bacteriol. 190:3155-3160.
44. Sarkar SK, Dutta M, Chowdhury C, Kumar A, Ghosh AS. 2011. PBP5, PBP6 and DacD play different roles in intrinsic beta-lactam resistance of Escherichia coli. Microbiology 157:2702-2707.
45. Song J, Bonner CA, Wolinsky M, Jensen RA. 2005. The TyrA family of aromatic-pathway dehydrogenases in phylogenetic context. BMC Biol. 3:13.
46. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40.
47. Brinster S, et al. 2009. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458:83-86.
48. Simmonds HA, Duley JA, Davies PM. 1991. Analysis of purine samples and pyrimidines in blood, urine, and other physiologic fluids, p 397-424. In Hommes F (ed), Techniques in diagnostic human biochemical genetics. A laboratory manual. Wiley-Liss, New York, NY.
49. Slocum RH, Cummings JG. 1991. Amino acid analysis of physiologic samples, p 87-126. In Hommes F (ed), Techniques in diagnostic human biochemical genetics. A laboratory manual. Wiley-Liss, New York, NY.
50. Russo TA, Jodush ST, Brown JJ, Johnson JR. 1996. Identification of two previously unrecognized genes (guaA, and argC) important for uropathogenesis. Mol. Microbiol. 22:217-229.
51. Altabe S, Lopez P, de Mendoza D. 2007. Isolation and characterization of unsaturated fatty acid auxotrophs of Streptococcus pneumoniae and Streptococcus mutans. J. Bacteriol. 189:8139-8144.
52. Zhang YM, White SW, Rock CO. 2006. Inhibiting bacterial fatty acid synthesis. J. Biol. Chem. 281:17541-17544.
53. Brinster S, et al. 2010. Reply: essentiality of FASII pathway for Staphylococcus aureus. Nature 463:E4-E5.
54. Lee BC, Schryvers AB. 1988. Specificity of the lactoferrin and transferrin receptors in Neisseria gonorrhoeae. Mol. Microbiol. 2:827-829.
55. Perkins-Balding D, Ratliff-Griffin M, Stojiljkovic I. 2004. Iron transport systems in Neisseria meningitidis. Microbiol. Mol. Biol. Rev. 68:154-171.
56. Hughes D. 2003. Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat. Rev. Genet. 4:432-441.
57. Silver LL. 2011. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24:71-109.
58. Murray CW, Blundell TL. 2010. Structural biology in fragment-based drug design. Curr. Opin. Struct. Biol. 20:497-507.
59. Scott DE, Coyne AG, Hudson SA, Abell C. 2012. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51: 4990-5003.
60. Silver LL. 2007. Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Discov. 6:41-55.
61. Ecker JA, et al. 2006. Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J. Clin. Microbiol. 44:2921-2932.
62. Adams MD, et al. 2008. Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J. Bacteriol. 190: 8053-8064.
63. Phogat SK, Gupta R, Burma PK, Sen K, Pental D. 2001. On the estimation of number of events required for saturation mutagenesis of large genomes. Curr. Sci. 80:823-824.
64. Johnson M, et al. 2008. NCBI BLAST: a better web interface. Nucleic Acids Res. 36:W5-W9.
65. Altenhoff AM, Schneider A, Gonnet GH, Dessimoz C. 2011. OMA 2011: orthology inference among 1000 complete genomes. Nucleic Acids Res. 39:D289-D294.
66. Knox C, et al. 2011. DrugBank 3.0: a comprehensive resource for "omics" research on drugs. Nucleic Acids Res. 39:D1035-D1041.
67. Zhu F, et al. 2012. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 40: D1128-D1136.